Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A genome-wide CRISPR Screen identifies targets that drive Tolerogenic Dendritic Cells

ABSTRACT: Tolerogenic dendritic cells (TolDCs) are essential for immune tolerance and have demonstrated therapeutic potential in early clinical studies of autoimmune diseases. However, the key molecular pathways driving their differentiation and tolerogenic phenotype remain elusive. Here we investigated the molecular mechanisms underlying the functional status of TolDCs in response to different tolerizing agents and identified CD86 as a consistent and robust marker downregulated in tolerogenic state. CD86 is functionally required for TolDC-mediated suppression of T cell proliferation and cytokine secretion, supporting its use as a surrogate marker of tolerogenic potential. Leveraging CD86 expression as a readout, we performed a genome-wide CRISPR-Cas9 knockout screen and identified regulators of TolDC-associated phenotypes. This approach uncovered UBE2L6 as a novel regulator of CD86 expression through modulation of an ISG15-USP18-associated pathway, implicating its involvement in tolerogenic functions. These findings identify therapeutically targetable pathways to promote immune tolerance.

ORGANISM(S): Mus musculus

PROVIDER: GSE348000 | GEO | 2026/09/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Generation of Induced Pluripotent Stem Cells Derived Tolerogenic Dendritic Cells and Their Immunosuppressive Properties.

Project description:Background: Dendritic cells (DCs), the primary antigen-presenting cells, regulate immune priming. DCs with a semi-mature phenotype and tolerogenic properties, termed tolerogenic DCs (tolDCs), are promising candidates for cell therapy to induce immune tolerance. Induced pluripotent stem cells (iPSCs) can provide an unlimited source of DCs, and in mice, tolDCs can be generated from bone marrow cells by adding agents such as minocycline and dexamethasone during DC differentiation. On this basis, we aimed to establish a protocol for generating tolDCs from iPSCs. Methods: We modified an existing iPSC-to-DC induction protocol by adding minocycline and dexamethasone. Then, we assessed whether the resulting cells exhibited tolDC characteristics through comparison of iPSC-derived DCs (iPS-DCs) and iPSC-derived tolDCs (iPS-tolDCs). Results: We established a method for generating iPS-tolDCs from iPSCs. Flow cytometric analysis revealed reduced expression of co-stimulatory molecules and the maturation marker in iPS-tolDCs compared with iPS-DCs. In co-culture experiments, CD4⁺CD45RA⁺ T cells isolated from PBMCs of healthy donors or patients with autoimmune diseases showed reduced proliferation when cultured with iPS-tolDCs compared with iPS-DCs. Gene expression profiles of iPS-tolDCs differed from those of iPS-DCs. Conclusion: We developed a protocol for producing tolDCs from iPSCs and demonstrated their tolerogenic phenotype and immunosuppressive effects on T cells. These findings indicate that iPS-tolDCs are a promising candidate for cellular immunotherapy and warrant further investigation.

2026-03-19 | GSE307178 | GEO

Dimethyl Fumarate Restores Functional Vitamin-D3 Tolerogenic Dendritic Cells differentiated from Multiple Sclerosis Patients

Project description:Multiple Sclerosis (MS) is a chronic disease characterised by dysregulated self-reactive immune responses damaging neurons’ myelin sheath, causing disability. The primary therapeutic option, immunosuppressants, inhibit pathogenic anti-myelin responses but depresses the entire immune system. Antigen-specific autologous tolerogenic dendritic cell (tolDC) therapies offer an approach to restore tolerance to auto-antigens without causing generalised immunosuppression. However, immune dysregulation in MS could impact the phenotype and functionality of the starting material for cell therapy. In this study, we defined the immune signature of CD14+ monocytes, mature dendritic cells (mDCs) and Vitamin D3 tolDCs (VitD3-tolDCs) isolated from MS patients and healthy donors (HD). By using a multi-omic approach, we identified a shift in these cell types toward a proinflammatory profile dominated by alterations in the AhR pathway and increased NFkB signalling. Moreover, tolDCs isolated from MS patients showed reduced tolerogenic properties compared to those from HD, which were fully restored through AhR agonism and NFkB downregulation through in vivo or in vitro supplementation with Dimethyl Fumarate (DMF). Remarkably, a combined therapy of DMF and VitD3-tolDC was more efficient to reduce the clinical score of experimental autoimmune encephalomyelitis mice than monotherapies. In summary, we demonstrate that DMF restores the functionality of VitD3-tolDCs derived from MS patients. Moreover, a combined therapy with DMF and VitD3-tolDCs could offer enhanced therapeutic potential in treating MS.

2024-12-13 | GSE267576 | GEO

Dimethyl Fumarate Restores Functional Vitamin-D3 Tolerogenic Dendritic Cells differentiated from Multiple Sclerosis Patients [Methylation_array]

2024-12-13 | GSE267660 | GEO

Microarray of tolerogenic dendritic cells differentiated in the presence of vitamin D3, dexamethasone or rapamycin

Project description:The comparative analysis of the transcriptome of tolerogenic dendritic cells (tolDC) differentiated using different stimulus (either vitamin D3, dexamethasone or rapamycin) would allow to evidence potential common genes and pathways that could explain their potency as tolerance-inducing cells.

2018-07-31 | E-MTAB-6937 | biostudies-arrayexpress

RNA-seq analysis of human T CD4+ cells after their interaction with autologous antigen-specific vitamin D3-generated tolerogenic dendritic cells

Project description:The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different alternatives available, the use of vitamin D3 for the generation of tolDC (vitD3‑tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. However, the mechanisms that vitD3‑tolDC are triggering for the induction of tolerance remain elusive. For this reason, we have performed a full transcriptomic characterization of T cells upon their interaction with autologous, antigen-specific vitD3-tolDC. Our results evidenced a strong down-modulation of genes involved in cell cycle and cell response to immune-related stimuli in T CD4+ cells after their interaction with vitD3-tolDC. Consequently, our results show the induction of a strong antigen-specific hyporresponsiveness, which manifests the regulatory properties of these cells and therefore their therapeutic potential in the clinic.

2020-12-21 | GSE128816 | GEO

Tolerogenic dendritic cells protect against acute kidney injury

Project description:We use tolDCs from syngeneic (C57BL6) and allogeneic (BALB/c) mice to show potent renoprotective abilities in a ischemia reperfusion AKI model. Dendritic cells were derived from mice bone marrow and cultured for 7 days with GM-CSF and IL-4. Tolerogenic DCs were cultured in the same DC media but with the addition of VitD3 and IL10. LPS was added on day 6 and cells harvested for use or analysis on day 7.

2024-11-25 | E-MTAB-14618 | biostudies-arrayexpress

Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells

Project description:Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4+ T cells. We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone. We found marked differences in the surface expression of HLA-DR and immune regulatory molecules, but also found commonalities, e.g. a strongly reduced capacity to produce interleukin-12 and a concomitant decreased ability to induce interferon- secretion by allogeneic CD4+ T cells. To gain a deeper understanding of how these tolDC types exert their regulatory effects, we co-cultured them with CD4+ T cells from rheumatoid arthritis patients or healthy controls and analysed the gene expression profile and function of the responding T cells. We found that tolDC generated with vitamin D3 alone, but not in combination with dexamethasone, induced potent cytotoxic activity in the responding CD4+ T cells as demonstrated by an enhanced cytotoxic gene signature, increased levels of intracellular granzyme B, and superior cytotoxic activity towards myeloid and B cells. These data identify cytotoxicity as an atypical CD4+ T helper cell effector function induced by some but not all tolDC types, with implications for their individual clinical applications.

2025-12-20 | GSE313751 | GEO

Transcription profiling of tolerizing murine cardiac allograft to understand the precise mechanisms of immunological tolerance.

Project description:C57/BL6 to C57/BL6; Balb/c to C57/BL6; Balb/c to C57/BL6 with anti CD80/86 mAb; Identificaton of gene expression profile in tolerizing murine cardiac allograft by co-stimulatory blockade. The induction of specific tolerance would be the ultimate achievement in transplant immunology, but the precise mechanisms of immunological tolerance remain largely unknown. Here, we investigated global gene expression analysis in tolerizing murine cardiac allografts by means of oligonucleotide microarrays. Tolerance induction was achieved in cardiac allografts from BALB/c to C57BL/6 mice by daily intraperitoneal injection of anti-CD80 and CD86 mAbs. Comparative analysis revealed 64 genes to be induced more extensively in the tolerizing than in the syngeneic isografts, and 16 genes than in the rejecting allografts. Two genes were specifically upregulated in the tolerizing allografts. In the tolerizing allografts there were induced marked expressions of a number of genes for proinflammatory factors, including interferon-gamma inducible cytokines and chemokines, as well as apoptosis-related genes which were also upregulated in the rejecting allografts. Moreover, these gene expression patterns continued to be upregulated more than 70 days post transplant. These results provide evidence that immunological tolerance can be induced and maintained in the presence of prominent proinflammatory gene expression in vivo.

2007-12-15 | E-GEOD-582 | biostudies-arrayexpress

Tolerogenic dendritic cells protect against acute kidney injury

2023-07-01 | GSE205322 | GEO

Tolerogenic Dendritic Cells Engineered with IL-10 and Antigen Control Pathogenic T Cell Responses and Promote Type 1 T Regulatory Cells

Project description:Dendritic cells (DC) play a critical role in the maintenance of tissue homeostasis and in promoting tolerance, thus acting as regulatory cells. Tolerogenic DC (tolDC) represent the cells of choice to fulfill the goal of restoring antigen (Ag)-specific tolerance since they can dampen Ag-specific T cell responses, induce pathogenic T cell exhaustion, and Ag-specific regulatory T cells. Here we efficiently generate tolDC by genetic engineering of monocytes with bidirectional lentiviral vectors co-encoding for immunodominant Ag-derived peptides (Ovalbumin or Matrix Protein 1, Insulin and Gliadin) in combination with IL-10 (DCIL-10/Ag). DCIL-10/Ag secrete high amounts of IL_x0002_10 in the absence of pro-inflammatory cytokines and efficiently modulate Ag-specific CD4+ and CD8+ T cell activation and proliferation in vitro in healthy subjects and Celiac Disease patients. DCIL-10/Ag promote Ag-specific CD49b+LAG-3 + T cells, which display the type 1 T regulatory (Tr1) cell gene signature in vitro. In vivo administration of DCIL-10/Ag promote Ag-specific Tr1 cells and prevent type 1 diabetes development in two murine models of disease. In conclusion, we generate an innovative approach based on the use of autologous engineered DC, which effectively modulate pathogenic CD4+ and CD8+ T cell responses in vitro and in vivo by promoting Ag_x0002_specific Tr1 cells suitable for cell-based therapy for restoring tolerance in T cell mediated diseases

2023-05-02 | GSE199425 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data